Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ying Shang

Showing results (351-360 of 363) with videos related to

Pageof 37
Sort By:
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|February 8, 2026
Progression of Liver Fibrosis and Liver-Related Event Risk in MASLD at High Cardiovascular RiskXiao-Dong Zhou, Qin-Fen Chen, Seung Up Kim, et al.
Gut|June 20, 2025
Non-invasive risk-based surveillance of hepatocellular carcinoma in patients with metabolic dysfunction-associated steatotic liver diseaseJimmy Che-To Lai, Boyu Yang, Hye Won Lee, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|February 1, 2026
ONE-YEAR CHANGES IN LSM, BUT NOT IN ALT AND CAP, PREDICT LONG-TERM LIVER OUTCOMES IN PATIENTS WITH MASLDGrazia Pennisi, Giuseppe Infantino, Gabriele Di Maria, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 11, 2025
A Novel Risk Prediction Model for Hepatocellular Carcinoma in MASLD: A Multinational, Multicenter Cohort StudyHo Soo Chun, Minjong Lee, Hye Ah Lee, et al.
Hepatology (Baltimore, Md.)|December 16, 2025
Cardiovascular-Kidney-Metabolic syndrome and the risk of liver fibrosis progression and liver-related events in MASLDXiao-Dong Zhou, Qin-Fen Chen, Qiong-Yue Fan, et al.
Gut|March 30, 2026
Two-step clinical care pathway to predict MASLD-related advanced fibrosis and long-term outcomes in type 2 diabetesYuping Chen, Bingtian Dong, Xinrui Jin, et al.
Hepatology (Baltimore, Md.)|November 13, 2025
Predictors of fibrosis, clinical events and mortality in MASLD: Data from the Global-MASLD studyZobair M Younossi, Leyla de Avila, Salvatore Petta, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|January 30, 2026
Diagnostic Accuracy of Non-Invasive Tests for MASLD Across Age, Type 2 Diabetes, and Obesity Subgroups: A Multinational StudyZobair M Younossi, Leyla de Avila, Salvatore Petta, et al.
Hepatology (Baltimore, Md.)|October 16, 2025
Global performance of non-invasive tests in MASLD: Insights from the G-MASLD studyZobair M Younossi, Leyla de Avila, Salvatore Petta, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|October 3, 2024
acFibroMASH Index for the Diagnosis of Fibrotic MASH and Prediction of Liver-related Events: An International Multicenter StudyGong Feng, Ferenc E Mózes, Dong Ji, et al.
Pageof 37

Showing results (351-360 of 363) with videos related to

Sort By:
Pageof 37
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|February 8, 2026
Progression of Liver Fibrosis and Liver-Related Event Risk in MASLD at High Cardiovascular RiskXiao-Dong Zhou, Qin-Fen Chen, Seung Up Kim, et al.
Gut|June 20, 2025
Non-invasive risk-based surveillance of hepatocellular carcinoma in patients with metabolic dysfunction-associated steatotic liver diseaseJimmy Che-To Lai, Boyu Yang, Hye Won Lee, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|February 1, 2026
ONE-YEAR CHANGES IN LSM, BUT NOT IN ALT AND CAP, PREDICT LONG-TERM LIVER OUTCOMES IN PATIENTS WITH MASLDGrazia Pennisi, Giuseppe Infantino, Gabriele Di Maria, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 11, 2025
A Novel Risk Prediction Model for Hepatocellular Carcinoma in MASLD: A Multinational, Multicenter Cohort StudyHo Soo Chun, Minjong Lee, Hye Ah Lee, et al.
Hepatology (Baltimore, Md.)|December 16, 2025
Cardiovascular-Kidney-Metabolic syndrome and the risk of liver fibrosis progression and liver-related events in MASLDXiao-Dong Zhou, Qin-Fen Chen, Qiong-Yue Fan, et al.
Gut|March 30, 2026
Two-step clinical care pathway to predict MASLD-related advanced fibrosis and long-term outcomes in type 2 diabetesYuping Chen, Bingtian Dong, Xinrui Jin, et al.
Hepatology (Baltimore, Md.)|November 13, 2025
Predictors of fibrosis, clinical events and mortality in MASLD: Data from the Global-MASLD studyZobair M Younossi, Leyla de Avila, Salvatore Petta, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|January 30, 2026
Diagnostic Accuracy of Non-Invasive Tests for MASLD Across Age, Type 2 Diabetes, and Obesity Subgroups: A Multinational StudyZobair M Younossi, Leyla de Avila, Salvatore Petta, et al.
Hepatology (Baltimore, Md.)|October 16, 2025
Global performance of non-invasive tests in MASLD: Insights from the G-MASLD studyZobair M Younossi, Leyla de Avila, Salvatore Petta, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|October 3, 2024
acFibroMASH Index for the Diagnosis of Fibrotic MASH and Prediction of Liver-related Events: An International Multicenter StudyGong Feng, Ferenc E Mózes, Dong Ji, et al.
Pageof 37